Kingsoft Cloud Holdings Limited (NASDAQ: KC) shares are 46.48% up in the year-to-date (YTD) period and have moved -2.65% or -$0.95 lower in the latest trading session. Comparatively, the stock is up 63.25% over the trailing 3-month period. If we look at the shorter duration, its week performance is 1.93% and 0.03% over the month.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
On June 08, 2020, JP Morgan recommended the KC stock is a Overweight, while earlier, Goldman had Initiated the stock as a Buy on June 29, 2020. 8 analysts offering the recommendations for the stock have a consensus rating of 2.00 to suggest that the KC stock is a “Moderate Buy. 0 of the 8 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 7 recommend buying, with 0 rating it as an Overweight.
The stock currently trades at $34.92 and analysts tracking its performance over the next 12 months have a consensus estimate price target of $45.93. The forecasts give the Kingsoft Cloud Holdings Limited stock a price target range of $492.77 on the higher side while at least one analyst think the stock could plunge to a low of $110.06. The two limits represent an upside potential of 92.91% or 68.27%.
Analysts also offered guidance for the next financial quarter, with their average projected EPS at between -$0.18 and -$0.15. Wall Street estimates earnings per share to be at an average of -$0.52 for the next year.
TherapeuticsMD Inc. (NASDAQ:TXMD), on the other hand, is trading around $1.49 with a market cap of $394.81M and analyst research firms have a positive stance on its shares. Some analysts are even forecasting -$0.64 per share in earnings this year on a short term (1 year) basis.
Let us briefly look at the TherapeuticsMD Inc. (TXMD) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
TXMD’s operating expenses over the recent quarter were at $51.74 million. This represented a -383.51% of the company’s total revenues which amounted $10.7 million. With this in place, we can see that the company’s diluted EPS declined -$0.19 on the year-over-year period, shrinking to -$0.23 as given in the last earnings report.
In terms of the balance sheet & cash flow as of (Sep 2020), the total assets figure advanced to $205.54 million from $268.64 million over the previous quarter. The cash flow from operating activities totaled -$95.1 million, significantly lower than the -$88.68 million reported in the year-ago quarter. The company’s free cash flow for the quarter was -$95.13 million.
Insiders have transacted a total of 8 times at TherapeuticsMD Inc. over the last 6 months, with insider purchases undertaken 8 times and accounting for 208,700 shares. Insider sales totaled 0 shares over the same period, with these deals completed in 0 transactions. Looking at these numbers, we realize that net purchases over that period are 8.0 shares. Insiders now hold a total of 34.49M shares after the latest sales, with 0.60% net shares purchased.
Insiders own 6.80% of the company shares, while shares held by institutions stand at 56.90% with a share float percentage of 238.66M. Investors are also buoyed by the number of investors in a company, with TherapeuticsMD Inc. having a total of 216 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 21.26 million shares worth more than $26.58 million. As of Jun 29, 2020, Blackrock Inc. held 7.81% of shares outstanding.
The other major institutional holder is Price (T.Rowe) Associates Inc, with the investment firm holding over 19.17 million shares as of Jun 29, 2020. The firm’s total holdings are worth over $23.96 million and represent 7.04% of shares outstanding.